I2U’s mandate is to support health system readiness and capacity for breakthrough medicines – and in doing so, accelerate the journey from idea to utilization.

Our foundational observation is that in Canada – and around the world – the steps from regulatory approval to reimbursement are defined by highly structured, well-established, and institution-heavy processes.  In contrast, after reimbursement, the launch of drugs into the market is dramatically different: with a set of approaches, mandates and responsibilities that frequently differ province-by-province, hospital-by-hospital and clinician-by-clinician.

This key insight helped clarify how and where I2U can make a meaningful, distinctive difference:  by helping to make sure the conversation around the market access of breakthrough medicines includes a sharp focus on what happens after reimbursement.

I2U’s work toward this goal is guided by an independent advisory board of experts in health system performance, technology utilization and knowledge translation: